In validation studies, TRX-311 demonstrated greater activity and selectivity in killing HCC tumor cells than standard of care, sorafenib, and significantly inhibited growth in two HCC patient-derived xenograft (PDX) tumor models. TRX-311 also demonstrated in vivo efficacy comparable to sorafenib with good tolerability.
Dr. Eller is an accomplished pharmaceutical industry executive who brings 30 years of R&D experience. Dr. Pandey is a leader in the pharmaceutical industry bringing 25 years of experience in all stages of drug discovery and development.
Allen’s experience forging strategic alliances in the life sciences industry will be a tremendous asset to twoXAR as the company continues to partner with leading biopharmaceutical companies to discover and develop first-in-class treatments for a wide range of diseases.
SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC).